Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017, Article ID 9561405, 4 pages
Case Report

The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy

Department of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

Correspondence should be addressed to Adam J. Cohen; ude.fsu.htlaeh@1nehoca

Received 25 April 2017; Accepted 9 July 2017; Published 14 August 2017

Academic Editor: Magnus Baumhäkel

Copyright © 2017 Vamsi C. Gaddipati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the treatment of heart failure. Pregnancy-associated cardiomyopathy (PACM) is a similar condition that refers to patients who develop such symptoms prior to the last month of pregnancy. We report the case of a nulliparous Caucasian female who develops early, severe PACM during her first pregnancy with postpartum persistence of New York Heart Association class II-III symptoms despite medical therapy. The use of the novel heart failure agent, sacubitril/valsartan (Entresto), is initiated with near-complete resolution of her symptoms.